Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

by Balicer, R., Barda, N., Dagan, N., Leader, A., Magen, O., Mittelman, M., Oster, H.S
Published 2022

Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination

by Al Jurdi, A., Alghamdi, A., Azzi, J.R, Bohan, B., Borges, T.J, Choi, J.Y, Cravedi, P., Efe, O., Gassen, R.B, Hullekes, F.E, Kotton, C.N, Lape, I.T, Mohammed, M.T, Patel, P., Pattanayak, V., Riella, L.V, Rosales, I., Solhjou, Z.
Published 2022

Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

by Ay, C., Barba, R., Bikdeli, B., Braester, A., Demelo-Rodriguez, P., Fidalgo, Á, for the RIETE Investigators, Galeano-Valle, F., Imbalzano, E., Jiménez, D., Lecumberri, R., Malý, R., Monreal, M., Ortiz, S., Porras, J.A, Rosa, V., Siniscalchi, C.
Published 2022

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

by Argimon, J.M, Ballo, E., Cabezas, C., Coma, E., Feng, S., Fina, F., Hermosilla, E., Martínez, M., Medina-Peralta, M., Méndez-Boo, L., Prieto-Alhambra, D., Xie, J.
Published 2022

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50

by Feng, S., Gea-Mallorquí, E., Li, X., Prats-Uribe, A., Prieto-Alhambra, D., Xie, J.
Published 2022

Deep Vein Thrombosis and Pulmonary Thrombosis After BNT162b2 mRNA SARS-CoV2 Vaccination

by Iwashima, S., Kurebayashi, N., Morikawa, S., Sawatari, C.
Published 2022

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)

by Akriv, A., Amichay, D., Avni, Y.S, Balicer, R.D, Barda, N., Berdinstein, R., Chayat, C.B, Chazan, B., Chowers, M., Dagan, N., Dor, A.B, Greenberg, D., Harlev, E.B, Hirsch, A., Katz, M.A, Kepten, E., Levy, J., Mandelboim, M., Peretz, A., Rainy, N., Rashid, G., Reznik, D., Sagas, D., Taraday, E.K, Tshori, S., Weinberger, R., Yacobi, M., Zuckerman, N., Zvi, H.B
Published 2022

Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol

by Caravagna, C.
Published 2022

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 202...

by Baida, N., Behl, S., Bennett, P.C, Berbert, L., Bhumbra, S.S, Bickford, M.M, Bline, K.E, Boom, J.A, Boutselis, B.J, Bowens, C., Bradford, T.T, Bruno, E.R, Cameron, M.A, Campbell, A.P, Carson, I.A, Chatani, B.M, Chen, S.R, Chiotos, K., Coates, B.M, Crane, K., Cullimore, M.L, Cvijanovich, N.Z, Dhanrajani, A., Douglas, R.L, Drapeau, N.M, Flori, H.R, Gaspers, M.G, Gertz, S.J, Goertzen, L.A, Golchha, M., Halasa, N.B, He, J., Heidemann, S.M, Hill, S.M, Hobbs, C.V, Hoody, L.A, Hume, J.R, Hussaini, L., Irby, K., Johnston, M.S, Kamidani, S., Kelley, C.P, Kietzman, A., Kong, M., Kucukak, S., Levy, E.R, Lionetti, G., Lockwood, J.M, Maamari, M., MacK, E.H, Maddux, A.B, Malloch, L., Martin, L., Michelson, K.N, Murcia-Montoya, J., Murdock, M., Navas, A.G, Newhams, M.M, Nofziger, R.A, Oates, J.N, Olson, S.M, Orzel, A.O, Overcoming COVID-19 Investigators, Pannaraj, P.S, Patel, M.M, Patterson, K., Peralta, H., Phengchomphet, K., Port, E., Price, A.M, Randolph, A.G, Rinehart, V.H, Rohlfs, C.C, Rowan, C.M, Sahni, L.C, Sanders, C., Sanders, R.C, Schuster, J.E, Schwartz, S.P, Skura, A.L, Smallcomb, L., Smith, C., Staat, M.A, Stewart, L.S, Stumpf, M., Tarquinio, K.M, Tomcany, M.L, Twinem, N.A, Typpo, K.V, Villarreal-Chico, D., Wakefield, L.E, Walker, T.C, Weller, E., Wolfe, A., Yates, M., Zambrano, L.D, Zinter, M.S
Published 2022

Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans

by Casas, J.P, Cho, K., Dickerman, B.A, Ferolito, B.R, Figueroa, M.J, Gagnon, D.R, Gaziano, J.M, Gerlovin, H., Hernán, M.A, Kurgansky, K.E, Madenci, A.L
Published 2022

Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

by Auclair, D., Ferrari, F., Fischer, E.S, Ghobrial, I.M, Hamilton, M., Horowitz, E., Justis, A.V, Konishi, Y., Lightbody, E.D, Marinac, C.R, Nowak, R.P, Perry, J., Prescott, J., Redd, R.A, Russo, M., Savell, A., Shayegh, N.A, Sklavenitis-Pistofidis, R., Trippa, L., Varmeh, S., Yue, H.
Published 2022

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

by Bromberg, M., Dichtiar, R., Glatman-Freedman, A., Hershkovitz, Y., Kaufman, Z., Keinan-Boker, L., Sefty, H.
Published 2022

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination

by Cipolletta, D., Corso, G., Fasanella, A., Foschino Barbaro, M.P, Galante, D., Morgese, M.G, Pace, L., Parisi, A., Pepe, G., Reveglia, P., Rosa, A.M, Sacco, R., Santo, I.B, Schiavone, S., Trabace, L., Tucci, P.
Published 2022

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel

by Balicer, R.D, Barda, N., Dagan, N., Makov-Assif, M., Netzer, D., Reis, B.Y, Waxman, J.G
Published 2022

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unschedul...

by Au, I.C.H, Chan, E.W.Y, Chui, C.S.L, Cowling, B.J, Lai, F.T.T, Lau, K.T.K, Lee, C.K, Li, X., Wan, E.Y.F, Wong, C.K.H, Wong, I.C.K, Xiong, X.
Published 2022